Effects of Icosapent Ethyl on Total Ischemic Events

2019253 citationsJournal Articlehybrid Open Access

Authors

Deepak L. Bhatt · Brigham and Women's Hospital

Philippe Gabríel Steg · Délégation Paris 7

Michael Miller · University of Maryland, Baltimore

Eliot A. Brinton · Louisville Metabolic and Atherosclerosis Research Center

Terry A. Jacobson · Emory University

Steven Ketchum · Amarin (United States)

Ralph T. Doyle

Abstract

Among statin-treated patients with elevated triglycerides and cardiovascular disease or diabetes, multiple statistical models demonstrate that icosapent ethyl substantially reduces the burden of first, subsequent, and total ischemic events. (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial [REDUCE-IT]; NCT01492361).

Topics & Keywords

Lipoproteins and Cardiovascular Health Fatty Acid Research and Health Diabetes, Cardiovascular Risks, and Lipoproteins

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the American College of Cardiology

Volume 73, Issue 22, pp. 2791-2802

DOI: 10.1016/j.jacc.2019.02.032

Field-Weighted Citation Impact: 40.06